ストックスクリーナーアプリを入手
0.839
3.31%
-0.0287
アフターアワーズ：
.84
0.001
+0.12%
前日終値:
$0.8677
開ける：
$0.8596
24時間の取引高:
92,473
Relative Volume:
0.04
時価総額：
$7.91M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.66%
1か月 パフォーマンス:
-58.26%
6か月 パフォーマンス:
-87.48%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.8178
$0.90
1週間の範囲:
$0.8178
$0.9758
52週間の値動き範囲:
$0.69
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
SCNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.839 | 7.91M | 0 | 0 | 0 | 0.00 |
|
WBA
Walgreens Boots Alliance Inc
|
10.87 | 9.43B | 147.66B | -8.64B | -363.00M | -10.01 |
|
WGRX
Wellgistics Health Inc
|
3.10 | 198.95M | 0 | 0 | 0 | 0.00 |
|
HITI
High Tide Inc
|
2.31 | 165.11M | 376.07M | -22.41M | 18.73M | -0.298 |
|
PETS
Petmed Express Inc
|
3.16 | 62.38M | 270.52M | -6.08M | 17.42M | -0.2944 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd
|
0.9337 | 13.97M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc (SCNX) 最新ニュース
Scienture Holdings Divests Subsidiaries to Tollo Health - MSN
Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa
Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - MarketScreener
Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener
Scienture Holdings divests subsidiaries for $5 million - Investing.com
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times
Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan
SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa
Scienture Holdings gears up for specialty pharma launches - Investing.com
Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks
Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK
Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView
Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register
Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times
Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan
3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scienture Holdings announces draw on Equity Line of Credit - MSN
Scienture announces draaw on Equity Line of Credit - TipRanks
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times
Organovo Announces Reverse Stock Split - The Manila Times
FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan
Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics
What's Going On With Scienture Shares Tuesday? - Benzinga
FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times
Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan
Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail
Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Scienture Holdings Inc (SCNX) Stock Behavior Isn’t As Predictable As You Think - Stocks Register
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Scienture Holdings appoints new CFO, stockholders vote at annual meeting By Investing.com - Investing.com Australia
Scienture Holdings appoints new CFO, stockholders vote at annual meeting - Investing.com
Scienture Holdings Appoints New CFO Eric Sherb - TipRanks
Scienture Holdings Secures Exclusive Naloxone Agreement - TipRanks
United States shares higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com
Best Stocks Under $5 Right Now - Benzinga
Scienture Holdings Inc (SCNX) 財務データ
Scienture Holdings Inc (SCNX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.51%
4.77%
大文字化:
|
ボリューム (24 時間):